anti-BCMA CAR-T
IIT2022064
Phase 2 mab active
Quick answer
anti-BCMA CAR-T for Plasma Cell Leukemia is a Phase 2 program (mab) at China SXT Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Program details
- Company
- China SXT Pharmaceuticals
- Indication
- Plasma Cell Leukemia
- Phase
- Phase 2
- Modality
- mab
- Status
- active